NewBridge Pharmaceuticals (NBP) is a first-in-class, venture-backed specialty therapeutics company focused on pharmaceuticals, biologics. NBP specializes in in-licensing, acquiring, registering and commercializing FDA, EMA/European and Japanese PMDA approved therapeutics to address the unmet medical needs of diseases with high regional prevalence in the Middle East, Africa, Turkey and Caspian (AfMET) regions.Our initial focus is on products for oncology and supportive care, metabolic disorders and gastro intestinal conditions. NewBridge also targets other specialty segments where medical and commercial synergies can be developed, and companies seeking to exit certain therapeutic areas. Future expansion includes establishing our own branded products through the establishment of manufacturing and R&D capabilities.Headquartered in Dubai, NBP has investment support from Burrill & Company (Burrill), a San Francisco-based global leader in life sciences with activities in venture capital, private equity, merchant banking and media, and the life science arm of National Technology Enterprises Company (NTEC), a Kuwait investment authority mandated fund operating out of Kuwait City. The Burrill/NTEC expansive life sciences network and partnership support provides NBP unprecedented access to U.S., European and Japanese biotechnology companies, products and investment expertise.NewBridge's innovative business model and efficient commercialization engine is built by successful and respected industry leaders with strong local and international track records. In addition, the NewBridge team has competencies in areas of registration, medical, pharmacovigilance and commercial capabilities acquired through years of experience in multinational pharma. The team is also well-connected to a wide range of partners and key stakeholders in and out of the region, and offers a flexible approach to joint-ventures and partnerships. This integrated and unique strategy of regional expertise and strong international access makes NewBridge the partner-of-choice, offering a one-stop-innovative model for pharmaceutical, biotechnology and other healthcare companies seeking to access the rapidly expanding markets of the AfMET regions.
